Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790850 | 0.97 | HTR1A (0.61) | HTR1ADRD4ADRA1AHTR1DHTR2B | |
| SCHEMBL792717 | 0.90 | HTR1A (0.64) | HTR1ADRD4ADRA1AHTR1DHTR2B | |
| SCHEMBL791927 | 0.90 | HTR7 (0.58) | HTR1ADRD4ADRA1AHTR1DHTR2B | |
| SCHEMBL791213 | 0.89 | DRD2 (0.57) | HTR1AHTR7DRD2 | |
| SCHEMBL791666 | 0.89 | L3MBTL1 (0.58) | HTR1AHTR7 | |
| SCHEMBL792716 | 0.89 | CCR1 (0.53) | HTR1ADRD4ADRA1AHTR7DRD2 | |
| SCHEMBL792618 | 0.87 | HTR1A (0.57) | HTR1ADRD4ADRA1AHTR1DHTR2B | |
| SCHEMBL790903 | 0.87 | HTR7 (0.55) | HTR1ADRD4ADRA1AHTR7DRD2 | |
| SCHEMBL792132 | 0.86 | L3MBTL1 (0.62) | HTR1ADRD2 | |
| SCHEMBL791311 | 0.86 | DRD2 (0.58) | HTR1AHTR2BHTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616440-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | Adamed sp. z o.o. (PL) | 2013-07-24 | — | — | EP | claimed |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z.O.O. (PL) | 2013-07-04 | — | — | US | claimed |
| WO-2012035123-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2012-03-22 | — | — | WO | claimed |
| US-9120767-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z.O.O. (PL) | 2015-09-01 | — | — | US | disclosed |
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2014-11-13 | — | — | US | disclosed |
| US-8822517-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z O.O. (PL) | 2014-09-02 | — | — | US | disclosed |
| EP-2616440-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | Adamed sp. z o.o. (PL) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z.O.O. (PL) | 2013-07-04 | — | — | US | disclosed |
| WO-2012035123-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | HTR1A 1354/4885DRD4 3761/4885ADRA1A 2795/4885 |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | HTR1A 1354/4885DRD4 3761/4885ADRA1A 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.